Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) COO Liane Rae Teplitsky purchased 1,001 shares of the stock in a transaction dated Tuesday, September 1st. The stock was bought at an average cost of $49.95 per share, with a total value of $49,999.95. Following the transaction, the chief operating officer owned 4,095 shares in the company, valued at $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Liane Rae Teplitsky also recently made the following trade(s):
- On Monday, August 31st, Liane Rae Teplitsky purchased 1,024 shares of Pulse Biosciences stock. The stock was purchased at an average price of $48.80 per share, for a total transaction of $49,971.20.
- On Friday, August 28th, Liane Rae Teplitsky acquired 1,034 shares of Pulse Biosciences stock. The shares were purchased at an average cost of $48.35 per share, for a total transaction of $49,993.90.
- On Wednesday, August 26th, Liane Rae Teplitsky acquired 1,036 shares of Pulse Biosciences stock. The shares were purchased at an average cost of $48.23 per share, for a total transaction of $49,966.28.
Pulse Biosciences Stock Performance
NASDAQ:PLSE opened at $52.68 on Thursday. The firm has a market cap of $3.65 billion, a P/E ratio of -44.64 and a beta of 1.63. Pulse Biosciences, Inc has a fifty-two week low of $12.56 and a fifty-two week high of $54.39. The firm has a 50-day simple moving average of $36.93 and a two-hundred day simple moving average of $27.60.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on PLSE shares. Needham & Company LLC began coverage on Pulse Biosciences in a research report on Monday, August 17th. They issued a “buy” rating and a $58.00 price objective on the stock. Mizuho set a $45.00 target price on Pulse Biosciences in a report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pulse Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $45.25.
Get Our Latest Stock Analysis on PLSE
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in Pulse Biosciences in the first quarter worth approximately $323,000. Creative Planning raised its stake in Pulse Biosciences by 26.3% during the 2nd quarter. Creative Planning now owns 18,971 shares of the company’s stock valued at $286,000 after buying an additional 3,951 shares during the last quarter. Legal & General Group Plc raised its stake in Pulse Biosciences by 57.7% during the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock valued at $338,000 after buying an additional 8,197 shares during the last quarter. Norges Bank bought a new position in shares of Pulse Biosciences during the 2nd quarter valued at $302,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Pulse Biosciences during the 2nd quarter valued at $158,000. 76.95% of the stock is owned by hedge funds and other institutional investors.
About Pulse Biosciences
Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.
Featured Articles
- Five stocks we like better than Pulse Biosciences
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
